A nasal COVID-19 vaccine developed by US biotech CyanVac has produced encouraging results in an early trial, showing potential to offer broader immunity and easier delivery than current injections.

Single dose vaccination with TNX-801 protects animals from a lethal challenge with monkeypox, the causative agent of mpox ...

A mid-stage trial of BPL‑003 nasal spray shows promising results for treatment-resistant depression, igniting biotech ...

Discover today's top 10 stocks in focus, key Q1 earnings, and major corporate actions - explore the latest market movers now!